The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement-Reference-Cited by-同舟云学术

The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement

Published:2021-02-02 Issue:9 Volume:147 Page:2637-2643
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Bilgin Burak^ORCID,Şendur Mehmet Ali Nahit,Yücel Şebnem,Hizal Mutlu,Güner Gürkan,Akyürek Nalan,Erol Cihan,Akıncı Muhammed Bülent,Dede Didem Şener,Yalçın Bülent,Kılıçkap Sadettin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-021-03546-1.pdf

Reference26 articles.

1. Camidge DR et al (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581–5590. https://doi.org/10.1158/1078-0432.CCR-10-0851

2. Camidge DR et al (2012) Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 118:4486–4494. https://doi.org/10.1002/cncr.27411

3. Camidge DR et al (2018) Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 379:2027–2039. https://doi.org/10.1056/NEJMoa1810171

4. Crino L et al (2016) Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol 34:2866–2873. https://doi.org/10.1200/JCO.2015.65.5936

5. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR (2010) Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer 116:5038–5046. https://doi.org/10.1002/cncr.25254

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?;Journal of Cancer Research and Clinical Oncology;2023-07-22

2. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study);Journal of Cancer Research and Clinical Oncology;2022-09-01